✦ LIBER ✦

A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV

✍ Scribed by P. Marcellin; G.K.K. Lau; H. Mommeja-Marin; S. Sacks; D. Sereni; J.P. Bronowicki; B. Conway; C. Trepo; E. Mondou; A. Snow; B.C. Yoo; H.S. Lee; F. Rousseau

Book ID: 117372404
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 162 KB
Volume: 38
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(03)80489-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trial: a phase II, randomized s

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B

✍ S. G. LIM; N. LEUNG; H. W. L. HANN; G. K. K. LAU; C. TREPO; H. MOMMEJA-MARIN; C. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

96 First clinical results for a novel an

96 First clinical results for a novel antiviral treatment for hepatitis C: A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283

✍ E. Godofsky; N. Afdhal; V. Rustgi; L. Shick; L. Duncan; X.J. Zhou; G. Chao; C. F 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Pharmacokinetics and tolerability of sin

Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trial

✍ Timothy Vollmer; Herbert R. Henney III 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 224 KB

A phase I dose-escalation study to evalu

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

✍ Desar, I M E; Timmer-Bonte, J N H; Burger, D M; van der Graaf, W T A; van Herpen 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 349 KB

626 Pharmacokinetics and pharmacodynamic

626 Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: Results from a phase I/II dose-escalation trial in patients with HCV-1 infection

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 107 KB

741 Safety, tolerability and antiviral a

741 Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study

✍ K.S. Lee; S.G. Lim; W.L. Chuang; S.G. Hwang; M. Cho; M.Y. Lai; Y.C. Chao; T.T. C 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 125 KB